{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+Therapy+%28ART%29&page=2",
    "query": {
      "intervention": "Antiretroviral Therapy (ART)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 560,
    "total_pages": 56,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+Therapy+%28ART%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antiretroviral+Therapy+%28ART%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T18:18:10.306Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01378494",
      "title": "Bone Mineral Density in HIV+ Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Osteoporosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2011-06",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2016-06-02",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01378494"
    },
    {
      "nct_id": "NCT03526848",
      "title": "3BNC117 and 10-1074 in ART-treated Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "3BNC117",
          "type": "DRUG"
        },
        {
          "name": "10-1074",
          "type": "DRUG"
        },
        {
          "name": "Analytical treatment interruption",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2018-06-05",
      "completion_date": "2022-02-11",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03526848"
    },
    {
      "nct_id": "NCT02706717",
      "title": "Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Visbiome Extra Strength",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2016-04",
      "completion_date": "2017-08-28",
      "has_results": true,
      "last_update_posted_date": "2020-01-06",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02706717"
    },
    {
      "nct_id": "NCT00298350",
      "title": "Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV",
        "HIV-1",
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GS-9137 - A Novel HIV-1 Integrase Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 278,
      "start_date": "2006-02",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2008-07-29",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 49 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00298350"
    },
    {
      "nct_id": "NCT00000899",
      "title": "A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 10,
      "start_date": null,
      "completion_date": "2001-10",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000899"
    },
    {
      "nct_id": "NCT03628287",
      "title": "Program Refinements to Optimize Model Impact and Scalability Based on Evidence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hiv"
      ],
      "interventions": [
        {
          "name": "Revised Care Coordination Program",
          "type": "OTHER"
        },
        {
          "name": "Original Care Coordination Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "City University of New York, School of Public Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 960,
      "start_date": "2018-08-01",
      "completion_date": "2023-01-31",
      "has_results": true,
      "last_update_posted_date": "2024-08-30",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 17,
      "location_summary": "Brooklyn, New York • Elmhurst, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Elmhurst",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03628287"
    },
    {
      "nct_id": "NCT00002227",
      "title": "A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Efavirenz",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dupont Merck",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 60,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 8,
      "location_summary": "Washington D.C., District of Columbia • Brookline, Massachusetts • Columbus, Ohio + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Brookline",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002227"
    },
    {
      "nct_id": "NCT06814275",
      "title": "Project neuroARTEMIS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stimulant Use",
        "Human Immunodeficiency Virus (HIV)",
        "Depression"
      ],
      "interventions": [
        {
          "name": "ARTEMIS",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Contingency management for Antiretroviral (ARV) adherence",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 189,
      "start_date": "2025-04-29",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06814275"
    },
    {
      "nct_id": "NCT01568892",
      "title": "Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir placebo twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-04-18",
      "completion_date": "2013-12-16",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 25,
      "location_summary": "Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01568892"
    },
    {
      "nct_id": "NCT00672191",
      "title": "Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "AGS-004",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Argos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 59,
      "start_date": "2008-02",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2013-01-29",
      "last_synced_at": "2026-10-07T18:18:10.306Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00672191"
    }
  ]
}